Status:
COMPLETED
Effects of Labetalol on Human Cocaine Use - 8
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
University of Minnesota
Conditions:
Cocaine-Related Disorders
Eligibility:
All Genders
20-45 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine.
Detailed Description
The goal of this study was to investigate the safety and utility of labetalol an alpha and beta adrenergic block, for cocaine dependence in humans. A total of 12 subjects were enrolled in this double ...
Eligibility Criteria
Inclusion Criteria:
Male/Female ages 20-55. History of smoked or intravenous cocaine use on the average of at least once a week over a six month period. Current history of good health and normal EKG. Not pregnant as determined by pregnancy screening nor breat feeding and using acceptable birth control methods (e.g. birth control pills diaphragm, condoms, plus foam) during the study.
Exclusion Criteria:
Current problems with major psychiatric illnesses including bipolar disorder, schizophrenia, or anxiety disorders. Current dependence on alcohol or on durgs other than cocaine. History of major medical illnesses including asthma and chronic obstructive pulmonary disease. Currently on a drug related parole or probation. Treated for chemical dependency within the past 6 months.
Key Trial Info
Start Date :
October 1 1997
Trial Type :
INTERVENTIONAL
End Date :
December 1 2001
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000291
Start Date
October 1 1997
End Date
December 1 2001
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455